Franco Nolè

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

François‐Clément Bidard, Dieter Peeters, Tanja Fehm et al. · The Lancet Oncology · 2014 · 815 citations

Metastatic Breast Cancer, Breast Oncology, Clinical Validity +8

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

Daniela Cardinale, Alessandro Colombo, Rosalba Torrisi et al. · Journal of Clinical Oncology · 2010 · 630 citations · Full text

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 533 citations

Surgical Oncology, Breast Oncology, Medicine +7

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad et al. · The Lancet Oncology · 2019 · 383 citations · Full text

Era 223, Urology, Medicine +8